EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data

Iker Elosua-Bayes iD, Alicia Alpuente iD, Laura Melgarejo, Edoardo Caronna iD, Marta Torres-Ferrús iD, Patricia Pozo-Rosich iD

Cephalalgia · 2024

DOI: 10.1177/03331024241273966 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cephalalgia, 2024. Verfasst von Iker Elosua-Bayes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelon…. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders, Pregnancy Complications, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review.

Methods

Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy. We collected data and conducted safety assessments. To provide a comprehensive context, we performed a literature review.

Results

The series includes three erenumab, two fremanezumab and one galcanezumab case. A fremanezumab recipient experienced miscarriage; severe perinatal asphyxia linked to dystocia occurred with erenumab (140 mg). Database reviews revealed 63 spontaneous abortions, eight premature births, and seven birth defects among 286 World Health Organization and 65 European Medicines Agency cases. These rates align with untreated population rates.

Conclusions

CGRP-mAbs use in the periconceptional period does not lead to clinically significant increase in pregnancy-related pathology or adverse effects on newborns within our case series and the literature reviewed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideMigraine DisordersPregnancy ComplicationsAntibodies, MonoclonalHumansFemalePregnancyAdultAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Stichwörter der Autor:innen

CGRP monoclonal antibodiesadverse drug reactionmigrainepregnancysafety

Substanzen

Calcitonin Gene-Related PeptideAntibodies, MonoclonalerenumabAntibodies, Monoclonal, HumanizedfremanezumabgalcanezumabCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Headache and Craniofacial pain Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

ORCID-Profile: Iker Elosua-Bayes, Alicia Alpuente, Edoardo Caronna, Marta Torres-Ferrús, Patricia Pozo-Rosich

Zitieren

APA

Elosua-Bayes, I., Alpuente, A., Melgarejo, L., Caronna, E., Torres-Ferrús, M., & Pozo-Rosich, P. (2024). Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data. Cephalalgia. https://doi.org/10.1177/03331024241273966

Vancouver

Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data. Cephalalgia. 2024. doi:10.1177/03331024241273966

BibTeX
@article{ElosuaBayes2024,
  author = {Elosua-Bayes, Iker and Alpuente, Alicia and Melgarejo, Laura and Caronna, Edoardo and Torres-Ferrús, Marta and Pozo-Rosich, Patricia},
  title = {Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024241273966}
}
Kostenlos starten →